Bernstein Liebhard LLP Reminds Investors of the Deadline to File a Lead Plaintiff Motion in a Securities Class Action Lawsuit Against Athira Pharma, Inc.

NEW YORK, June 30, 2021 / PRNewswire / – Bernstein Liebhard, a nationally recognized investor rights law firm, is reminding investors of the deadline to file a motion by the lead plaintiff in a securities class action filed on behalf of investors who bought or acquired the securities of Athira Pharma, Inc . (“Athira” or the “Company”) (NASDAQ: ATHA) of September 18, 2020 by June 17, 2021 (the “Class Period”). The lawsuit filed in The United States District Court for the Western District of Washington alleges violations of the 1934 Stock Exchange Act.

If you have purchased Athira securities and / or would like to discuss your statutory rights and options, please visit or contact the Athira Shareholder Class Action Joseph R. Seidman Jr. toll free at (877) 779-1414 or [email protected]

The lawsuit alleges that throughout the class action period, defendants made substantially false and misleading statements and omitted material adverse facts relating to the company’s business. Specifically, Defendants have failed to advise investors: (1) that the investigations conducted by Athira’s President and CEO Leen Kawas |, which formed the basis of Athira’s product candidates and intellectual property, was tainted by Kawas’ scientific misconduct, including manipulation of key data; and (2) that, based on the foregoing, Defendants’ positive statements about the Company’s business, operations and prospects were materially misleading and essential facts were omitted that are necessary to avoid misleading statements.

On June 17, 2021After the market closed, Athira issued a press release announcing that the board of directors of the Kawas company was on a temporary leave of absence pending a review of the measures based on doctoral theses carried out during his studies Washington State University. An article published later that day in STAT News revealed that Kawas’ investigation is related to allegations that she has images in four separate articles related to her research on hepatocyte growth factor (HGF), a protein with the potential to treat the disease Alzheimer’s disease.

On the news, Athira’s share price fell $ 7.09 per share, or nearly 39%, to at. close $ 11.15 per share June 18, 2021, with unusually high trading volumes.

If you want to appear as the main plaintiff, you must notify the court by no August 24, 2021. A lead plaintiff is a representative party who acts on behalf of other group members in directing the dispute. Your ability to partake in a recovery does not require you to be the lead plaintiff. If you do nothing, you can remain an absent class member.

If you have purchased Athira securities and / or would like to discuss your legal rights and options, please visit https://www.bernlieb.com/cases/athirapharmainc-atha-shareholder-class-action-lawsuit-fraud-stock-407 / apply / or contact Joseph R. Seidman Jr. toll free at (877) 779-1414 or [email protected]

Bernstein Liebhard LLP has been recovering since 1993 $ 3.5 billion for its customers. In addition to representing individual investors, the firm has been hired by some of the country’s largest public and private pension funds to monitor their assets and litigate on their behalf. As a result of its success in hundreds of lawsuits and class actions, the firm has been listed on the National Law Journal’s “Plaintiffs’ Hot List” thirteen times and The Legal 500 for ten consecutive years.

ADVERTISING LAWYER. © 2021 Bernstein Liebhard LLP. The firm responsible for this ad is Bernstein Liebhard LLP, 10 East 40th Street, New York, New York 10016, (212) 779-1414. The lawyer responsible for this report im State of Connecticut is Michael S. Bigin. Past results do not guarantee or predict a similar result with respect to future matters.

Contact information

Joseph R. Seidman Jr.
Bernstein Liebhard LLP
https://www.bernlieb.com
(877) 779-1414
[email protected]

SOURCE Bernstein Liebhard LLP

similar links

http://www.bernlieb.com

Comments are closed.